| Project/Area Number |
15K07905
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Suzuka University of Medical Science |
|---|
Principal Investigator |
Komeda Seiji 鈴鹿医療科学大学, 薬学部, 准教授 (60425056)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
植村 雅子 鈴鹿医療科学大学, 薬学部, 助教 (70511997)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HIRAMOTO Keiichi 鈴鹿医療科学大学, 薬学部, 助教 (90251793)
HARUSAWA Shinya 大阪薬科大学, 薬学部, 教授 (90167601)
YONEYAMA Hiroki 大阪薬科大学, 薬学部, 助教 (90627001)
YOSHIKAWA Yuko 同志社大学, 生命医科学部, 嘱託講師 (80291871)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 白金錯体 / 制がん剤 / DDS / 創薬 / 難治性がん / 白金製剤 / オキサリプラチン / 大腸がん / 抗腫瘍効果 / 細胞内蓄積 / 白金制がん剤 / 金属錯体 / 核酸 / 細胞内取込 / 薬物耐性 |
|---|
| Outline of Final Research Achievements |
New tetrazolato-bridged dinuclear platinum(II) complexes were designed and synthesized to combine with DDS carrier or to introduce halogen into the complexes. Our in vivo study using mice with a subcutaneous homograft of Colon-26 colorectal cancer cells indicates that the tetrazolato-bridged dinuclear platinum(II) complexes are promising next-generation platinum-based drug candidates with markedly high and long-lasting antitumor efficacy. Indeed, the tumour growth in mice treated with the lead compound was much slower than that in mice treated with platinum-based drug oxaliplatin, which is used for the treatment of colorectal cancer. Even more remarkable, the lead compound exhibited high tumor-reduction effects against large-sized tumours, which sustained for a few weeks after a single intravenous dose of the compound.
|
